A new bispecific antibody targeting T-cell CD3 and TYRP1, a protein overexpressed in over 50% of mM tumor cells, allows directs tumor–T-cell engagement without requiring MHC presentation or an APC [77]. Here, TYRP1 is linked to neoplasm.